Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091077 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01091077: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01091077 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01091077, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Hepatitis C virus when it leaves the cells in the liver is bound to a type of fat. An component of grapefruit could block this fat and thus lower the amount of virus in the blood stream. We propose that treatment with this ingredient, called naringenin, could be used to block this fat and HCV in persons infected with hepatitis C.
Primary Outcome
Level of naringenin will be measured by HPLC at time 0, 30, 40, 90, 120, 150, and 180 min and at 4, 5, 6, 7, 8, and 12 hours.
Interventions
- DIETARY_SUPPLEMENT Naringenin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
What the finished NCT01091077 record still lists
NCT01091077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Naringenin is the first listed.
NCT01091077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01091077 about?
NCT01091077 is a clinical study titled "A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection". Hepatitis C virus when it leaves the cells in the liver is bound to a type of fat. An component of grapefruit could block this fat and thus lower the amount of virus in the blood stream. We propose that treatment with this ingredient, called naringenin, could be used to block this fat and HCV in per...
What is the current status of trial NCT01091077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-06. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01091077?
The interventions under investigation include: Naringenin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01091077?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01091077's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia